Satellos Bioscience Inc · TSX:MSCL
Satellos Bioscience — Investor Presentation (February 2023)
21 slides from Satellos Bioscience's investor presentation, February 2023

Slide 1: Satellos Bioscience Inc. Non-Confidential Overview
FEBRUARY 2023 SATELLOS BIOSCIENCE INC. NON-CONFIDENTIAL OVERVIEW Omnis cellula e cellula Rudolph Virchow c.1858 1

Slide 2: Legal Disclaimers
2 Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or perfor

Slide 3: Satellos: Revolutionizing the treatment of muscle disorders
3 Satellos: Revolutionizing the treatment of muscle disorders Pivotal Discoveries Signaling role for dystrophin in muscle stem cells1 Dystrophin drives polarity and regeneration in Duchenne muscular dystrophy Pathways which can be modulated with drug to restore polarity and regeneration De

Slide 4: Dystrophin's role in stem cells outweighs role in fibers
4 Dystrophin’s role in stem cells outweighs role in fibers Orthodox view: Satellos discovery: Dystrophin in fibers provides structure Dystrophin in stem cells drives regeneration 2x10-12 Dystrophin expressed in Dystrophin expressed in muscle fibers muscle stem cells Orthodox solution: genetic therap

Slide 5: Refresher: How muscle stem cell polarity drives regeneration
5 Refresher: How muscle (satellite) stem cell polarity drives regeneration Normal Stem Cell: Duchenne Stem Cell: Polarity and Regeneration Enabled Polarity and Regeneration Impaired Muscle fiber Muscle fiber 2x10-12 N S Par1b Dystrophin Return to quiescence Basal lamina Basal lamina Polarity and reg

Slide 6: 3rd party evidence supports Satellos approach
6 3rd party evidence supports Satellos approach 2010 Clinicians observe elevated stem cells in Duchenne patients Supports thesis of deficit in asymmetric divisions Significance not understood at the time 2016 Kunkel group identifies Dystrophin null escaper dogs Regeneration implicated but

Slide 7: Target and Proof of Concept
Target and Proof of Concept: • Identified kinase (codenamed ‘K9) as polarity ‘switch’ • Rapid effect on muscle regeneration with drug treatment • Linear dose response in force generation 7

Slide 8: IP Landgrab: novel screening platform identified polarity regulators
IP Landgrab: Satellos’ novel screening platform identified polarity regulators Input Output Targets Curated siRNA Library Targets affecting polarity Priority Pathway MyoReGenXTM NOTCH (via K9*) * * Identified Notch/K9 as capable of rescuing polarity in Mdx * Codename

Slide 9: "K9" an appealing, druggable target
9 “K9” an appealing, druggable target Known Protein Under Development in “K9” Human Safety “K9” Role in Muscle Different Disease Area Profile Stem Cells “K9” Two Phase 1 studies Symmetric division Not previously pursued in Duchenne no serious adverse modulation of Notch models to best of o

Slide 10: POC (study #1): Progenitor Cells
10 POC (study #1): “K9” inhibition with drug rapidly shows effect on polarity On mechanism Experimental Design Drug* Day 0 Day 17 (No. Myog+ per mm2) (No. Pax7+ per mm2) Progenitor Cells Stem Cells Four doses given intermmitently Mdx mice Analysis n = 5/group Control Drug Control Drug Stem cells Pro

Slide 11: Striking effect on progenitors and regeneration capacity
11 Striking effect on progenitors and regeneration capacity Control Drug Treated Myogenin expression, a marker for progenitors, corresponds to areas of focal damage Pax7 is a marker for stem cells | Myogenin for progenitors

Slide 12: Significant regeneration of muscle c. 40%
12 Significant regeneration of muscle c. 40% (NB., each image is from the TA muscle of a separate Mdx mouse) Control Drug Treated 12

Slide 13: POC (study #2): Rapid increase in muscle force
13 POC (study #2): Rapid increase in muscle force in dose dependent manner Study 2: Similar design to study 1, 3 dose groups, n=7 per group We estimate mdx strength to be roughly 70% of normal at this age suggesting muscle strength is being restored to near normal capacity with only two weeks of dru

Slide 14: Status and Plan: Chemistry, Timeline, Budget
Status and Plan: Chemistry, Timeline, Budget 14

Slide 15: Novel chemical matter
15 Novel chemical matter: Three series developed by AI/ML and de-novo design SERIES A SERIES B/C Lead Compound Series Back-up/Second Compound Series Nanomolar potency Picomolar potency ADME, PK, and Kinome selectivity Advanced SAR/optimization ongoing Activity in Mdx models Selectivity p

Slide 16: Satellos timeline: Strong value catalysts over next months
16 Satellos timeline: Strong value catalysts over next 18 months Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Lead program - Duchenne SAT-3153 Phase I completed Lead Compound CMC IND-enabling Studies FDA submission Pre-IND meeting with FDA POC development in other disease areas Additional philanthropic

Slide 17: Lead Development Program in Place
17 Lead Development Program in Place CMC IND-Enabling Studies Clinical Relationship with provider Study slots secured with CRL Phase 1 established analytical validation Healthy volunteers general toxicology Phase 2 Simple, cost-effective synthetic small & large species In talks w

Slide 18: Corporate: Cap Table, Team
Corporate: Cap Table Team 18

Slide 19: Background and Cap Table
19 Background and Cap Table BACKGROUND CAPITAL TABLE Founded 04/2018 by repeat players Common Shares 41,800,000 Warrants 5,300,000 RTO on TSX.V on 08/13/2021 Stock options 4,000,000 CDN$18m raised cumulatively Fully Diluted 51,100,000 Venture philanthropy partner Insiders: ~27% (fully dilute

Slide 20: Experienced Board and Scientific Excellence
Experienced Board 20 Geoffrey Mackay Adam Mostafa Rima Al-awar, PhD William McVicar, PhD William Jarosz, JD Frank Gleeson, MBA Chair — Board of Directors Chair – Audit Committee Board Member Board Member & Advisor CEO – AmpB Technologies Inc. Co-Founder & CEO Founder and CEO - CFO - X4 Head –

Slide 21: Thank You!
THANK YOU! SATELLOS BIOSCIENCE INC. Rebuilding muscle from within TM Satellos Bioscience Inc. | Att’n: Frank Gleeson, CEO 79 Wellington Street West, 33rd Floor, Toronto, Ontario M5K 1N2 21 647-660-1780 | info@satellos.com
Source: Internet Archive copy of satellos.com
More decks from Satellos Bioscience Inc
Corporate Update (November 2026)17 slides · Nov 6, 2026
Corporate Update (July 2026)14 slides · Jul 8, 2026
2026 Bloom Burton & Co. Healthcare Investor Conference23 slides · April 2026
Technical Presentation (February 2026)52 slides · Feb 24, 2026
Investor Presentation (February 2026)21 slides · February 2026
Investor Presentation (October 2025)19 slides · October 2025